156 related articles for article (PubMed ID: 15234045)
1. Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study.
Schulz CA; Mehta MP; Badie B; McGinn CJ; Robins HI; Hayes L; Chappell R; Volkman J; Binger K; Arzoomanian R; Simon K; Alberti D; Feierabend C; Tutsch KD; Kunugi KA; Wilding G; Kinsella TJ
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1107-15. PubMed ID: 15234045
[TBL] [Abstract][Full Text] [Related]
2. Iododeoxyuridine (IUdR) combined with radiation in the treatment of malignant glioma: a comparison of short versus long intravenous dose schedules (RTOG 86-12).
Urtasun RC; Cosmatos D; DelRowe J; Kinsella TJ; Lester S; Wasserman T; Fulton DS
Int J Radiat Oncol Biol Phys; 1993 Sep; 27(2):207-14. PubMed ID: 8407393
[TBL] [Abstract][Full Text] [Related]
3. National Cancer Institute (phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: results in anaplastic astrocytoma.
Sullivan FJ; Herscher LL; Cook JA; Smith J; Steinberg SM; Epstein AH; Oldfield EH; Goffman TE; Kinsella TJ; Mitchell JB
Int J Radiat Oncol Biol Phys; 1994 Oct; 30(3):583-90. PubMed ID: 7928489
[TBL] [Abstract][Full Text] [Related]
4. Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study.
McGinn CJ; Kunugi KA; Tutsch KD; Feierabend C; Alberti D; Lindstrom MJ; Wilding G; Arzoomanian RZ; Kinsella TJ
Clin Cancer Res; 1996 Aug; 2(8):1299-305. PubMed ID: 9816300
[TBL] [Abstract][Full Text] [Related]
5. Phase I and Pharmacology Study of Ropidoxuridine (IPdR) as Prodrug for Iododeoxyuridine-Mediated Tumor Radiosensitization in Advanced GI Cancer Undergoing Radiation.
Kinsella T; Safran H; Wiersma S; DiPetrillo T; Schumacher A; Rosati K; Vatkevich J; Anderson LW; Hill KD; Kunos C; Collins JM
Clin Cancer Res; 2019 Oct; 25(20):6035-6043. PubMed ID: 31337643
[TBL] [Abstract][Full Text] [Related]
6. 5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis.
Vokes EE; Dolan ME; Krishnasamy S; Mick R; Ratain MJ; Berezin F; Brachman D; Whitman G; Schilsky RL; Charette J
Ann Oncol; 1993 Aug; 4(7):591-5. PubMed ID: 8395874
[TBL] [Abstract][Full Text] [Related]
7. Synthetic, implantable polymers for IUdR radiosensitization of experimental human malignant glioma.
Yuan X; Dillehay LE; Williams JR; Williams JA
Cancer Biother Radiopharm; 1999 Jun; 14(3):187-202. PubMed ID: 10850303
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of intravenous iododeoxyuridine as a clinical radiosensitizer.
Kinsella TJ; Russo A; Mitchell JB; Collins JM; Rowland J; Wright D; Glatstein E
Int J Radiat Oncol Biol Phys; 1985 Nov; 11(11):1941-6. PubMed ID: 2997090
[TBL] [Abstract][Full Text] [Related]
9. PET imaging drug distribution after intratumoral injection: the case for (124)I-iododeoxyuridine in malignant gliomas.
Roelcke U; Hausmann O; Merlo A; Missimer J; Maguire RP; Freitag P; Radü EW; Weinreich R; Gratzl O; Leenders KL
J Nucl Med; 2002 Nov; 43(11):1444-51. PubMed ID: 12411546
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology and phase I/II study of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multiforme.
Kinsella TJ; Collins J; Rowland J; Klecker R; Wright D; Katz D; Steinberg SM; Glastein E
J Clin Oncol; 1988 May; 6(5):871-9. PubMed ID: 2835444
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine-mediated radiosensitization in mouse and human tissues.
Kinsella TJ; Kunugi KA; Vielhuber KA; Potter DM; Fitzsimmons ME; Collins JM
Clin Cancer Res; 1998 Jan; 4(1):99-109. PubMed ID: 9516958
[TBL] [Abstract][Full Text] [Related]
12. Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma.
Chang EL; Loeffler JS; Riese NE; Wen PY; Alexander E; Black PM; Coleman CN
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):65-70. PubMed ID: 9422559
[TBL] [Abstract][Full Text] [Related]
13. Intraarterial iododeoxyuridine infusion combined with irradiation. A pilot study.
Wirtanen GW; Wiley AL; Vermund H; Stephenson JA; Ansfield FJ
Am J Clin Oncol; 1990 Aug; 13(4):320-3. PubMed ID: 2378311
[TBL] [Abstract][Full Text] [Related]
14. Treatment of locally advanced cancer of the head and neck with 5'-iododeoxyuridine and hyperfractionated radiation therapy: measurement of cell labeling and thymidine replacement.
Epstein AH; Lebovics RS; Goffman T; Teague D; Fuetsch ES; Glatstein E; Okunieff P; Cook JA
J Natl Cancer Inst; 1994 Dec; 86(23):1775-80. PubMed ID: 7966416
[TBL] [Abstract][Full Text] [Related]
15. Implantable biodegradable polymers for IUdR radiosensitization of experimental human malignant glioma.
Williams JA; Dillehay LE; Tabassi K; Sipos E; Fahlman C; Brem H
J Neurooncol; 1997 May; 32(3):181-92. PubMed ID: 9049879
[TBL] [Abstract][Full Text] [Related]
16. Preclinical toxicity and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine radiosensitization in U251 human glioblastoma xenografts.
Kinsella TJ; Vielhuber KA; Kunugi KA; Schupp J; Davis TW; Sands H
Clin Cancer Res; 2000 Apr; 6(4):1468-75. PubMed ID: 10778979
[TBL] [Abstract][Full Text] [Related]
17. Impact of IUdR on Rat 9L glioma cell survival for 25-35 keV photon-activated auger electron therapy.
Alvarez D; Hogstrom KR; Brown TA; Ii KL; Dugas JP; Ham K; Varnes ME
Radiat Res; 2014 Dec; 182(6):607-17. PubMed ID: 25409122
[TBL] [Abstract][Full Text] [Related]
18. Measurement of thymidine replacement in patients with high grade gliomas, head and neck tumors, and high grade sarcomas after continuous intravenous infusions of 5-iododeoxyuridine.
Cook JA; Glass J; Lebovics R; Bobo H; Pass H; DeLaney TF; Oldfield EH; Mitchell JB; Glatstein E; Goffman TE
Cancer Res; 1992 Feb; 52(3):719-25. PubMed ID: 1732059
[TBL] [Abstract][Full Text] [Related]
19. Enhancement radiation-induced apoptosis in C6 glioma tumor-bearing rats via pH-responsive magnetic graphene oxide nanocarrier.
Shirvalilou S; Khoei S; Khoee S; Mahdavi SR; Raoufi NJ; Motevalian M; Karimi MY
J Photochem Photobiol B; 2020 Apr; 205():111827. PubMed ID: 32120183
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of cell labeling and thymidine replacement after continuous infusion of halogenated pyrimidines in vivo.
Rodriguez R; Ritter MA; Fowler JF; Kinsella TJ
Int J Radiat Oncol Biol Phys; 1994 Apr; 29(1):105-13. PubMed ID: 8175417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
